Augustine Therapeutics focuses on the discovery and development of innovative medicines to benefit patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular diseases. CMT is one of the most common hereditary disorders of the peripheral nervous system, affecting approximately 10 to 30 in 100,000 people globally.
Investors 2
| Date | Name | Website |
| - | V-Bio Vent... | v-bio.vent... |
| - | KU Leuven ... | lrd.kuleuv... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 02.03.2023 | CMT Research Foundation (USA) collaborates with Augustine on... | Augustine Therapeutics Logo LEUVEN, BELGIUM, March 2, 2023 /EINPresswire.com/ -- Augustine Therapeu... | einpresswi... |
| 10.05.2022 | Augustine Therapeutics appoints Gerhard Koenig as Chairman o... | Augustine Therapeutics Logo LEUVEN, BELGIUM, May 10, 2022 /EINPresswire.com/ -- Augustine Therapeut... | einpresswi... |